{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"88.0","value":"61.5"},{"groupId":"OG001","lowerLimit":"35.1","upperLimit":"88.0","value":"61.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of stable disease (SD) sustained for at least 8 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-participant basis to 50 mg and then 75 mg, based on the participant's response to and tolerance of therapy, in 28-day cycles.","id":"OG000","title":"Dose Optimization Phase: Cohort 1"},{"description":"Duvelisib 75 mg PO BID, administered in 28-day cycles.","id":"OG001","title":"Dose Optimization Phase: Cohort 2"}],"paramType":"NUMBER","populationDescription":"Dose Optimization Efficacy Set: All participants who received at least one dose of study drug, completed at least one cycle of treatment, and had at least one scan to assess disease response after completion of one cycle of treatment. As pre-specified, efficacy analysis using investigator assessment reported for the Dose Optimization Phase only.","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks","title":"Disease Control Rate (DCR) As Assessed by the Investigator Using the Lugano Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}